Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 17,001 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ELEVATE Clear all
Completed Phase 1 Interventional

A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission

NCT01632852
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
CSL362
Biological
Lead sponsor
CSL Limited
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 24, 2026, 2:20 AM EDT
Completed Phase 2 Interventional Results available

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome

NCT00968071
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Decitabine, Gemtuzumab Ozogamicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 24, 2026, 2:20 AM EDT
Completed Phase 1 Interventional

Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

NCT00687934
View directory record Official record
Conditions
Solid Tumors
Interventions
STA-9090
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
25 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Santa Monica, California • Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 24, 2026, 2:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer

NCT01662609
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Endoscopic Ultrasound (EUS)
Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
30 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2022
U.S. locations
2
States / cities
Tampa, Florida • Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 24, 2026, 2:20 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT05405309
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
RP-3500, Olaparib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 24, 2026, 2:20 AM EDT
Completed Not applicable Interventional

High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer

NCT00243321
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
high dose-rate brachytherapy, intensity-modulated radiation therapy
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 24, 2026, 2:20 AM EDT
Completed Phase 4 Interventional Results available

A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)

NCT04320316
View directory record Official record
Conditions
Epidermal Nevus Syndrome
Interventions
Crysvita (burosumab-twza) Treatment
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Months and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 24, 2026, 2:20 AM EDT
Completed No phase listed Observational

Cognitive Assessment in COVID-19 Positive Patients Using the DANA App

NCT05143333
View directory record Official record
Conditions
COVID-19
Interventions
DANA app
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 24, 2026, 2:20 AM EDT
Terminated Phase 3 Interventional Results available

Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery

NCT01086852
View directory record Official record
Conditions
Factor X Deficiency
Interventions
FACTOR X
Biological
Lead sponsor
Bio Products Laboratory
Other
Eligibility
12 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 24, 2026, 2:20 AM EDT
Completed Not applicable Interventional

Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas

NCT01653834
View directory record Official record
Conditions
Glioblastoma
Interventions
Lymphocyte harvesting & reinfusion
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 24, 2026, 2:20 AM EDT
Completed Phase 3 Interventional Results available

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

NCT00671034
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Calaspargase Pegol-mknl, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Pharmacological Study, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 30 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Orange, California • Palo Alto, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 24, 2026, 2:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Short Duration High-intensity Interval Training on Peak Oxygen Consumption

NCT04656509
View directory record Official record
Conditions
Cardiovascular Fitness
Interventions
4-s sprint inertial load training
Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 49 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 24, 2026, 2:20 AM EDT
Completed Phase 2 Interventional

A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence

NCT00749632
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
oxybutynin
Drug
Lead sponsor
FemmePharma Global Healthcare, Inc.
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Oct 24, 2026, 2:20 AM EDT
Completed Phase 1 Interventional

WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors

NCT04334863
View directory record Official record
Conditions
Brain Tumor, Medulloblastoma, Brain Metastases
Interventions
WP1066
Drug
Lead sponsor
Emory University
Other
Eligibility
3 Years to 25 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 24, 2026, 2:20 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

NCT03033914
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
9
States / cities
Detroit, Michigan • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 24, 2026, 2:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

NCT03254784
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
Interventions
BMS-986165 Capsule, BMS-986165 Tablet
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 24, 2026, 2:20 AM EDT
Recruiting Phase 2 Interventional

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Rituximab Biosimilar, Prednisone, Prednisolone, Polatuzumab vedotin, Rescue Medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
73
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 24, 2026, 2:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Study to Investigate the Tooth Stain Removal Efficacy of Two Experimental Toothpastes Compared to a Standard Toothpaste When Used Twice Daily for 8 Weeks

NCT05459558
View directory record Official record
Conditions
Oral Hygiene
Interventions
Experimental Dentifrice 1, Experimental Dentifrice 2, Reference Dentifrice
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 65 Years
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 24, 2026, 2:20 AM EDT
Completed Not applicable Interventional Results available

Behavioral Approaches to Reducing Diabetes Distress and Improving Glycemic Control

NCT04016558
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes Distress
Interventions
StreamLine, TunedIn, FixIt
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
19 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 24, 2026, 2:20 AM EDT
Not listed Phase 1Phase 2 Interventional

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer

NCT00002628
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
3
States / cities
Indianapolis, Indiana • St Louis, Missouri • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 24, 2026, 2:20 AM EDT
Active, not recruiting Not applicable Interventional

Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage

NCT06655207
View directory record Official record
Conditions
Post Partum Haemorrhage, Maternal Care Patterns, High Risk Pregnancy
Interventions
Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding
Device
Lead sponsor
Baymatob Operations Pty Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Denver, Colorado • Baton Rouge, Louisiana • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 24, 2026, 2:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Vitamin D Insufficiency

NCT00933244
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
High Dose Vitamin D3, Low Dose Vitamin D3, Placebo
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Up to 75 Years · Female only
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 24, 2026, 2:20 AM EDT
Recruiting No phase listed Observational

Metabolic Inflexibility is Related to Elevated Muscle Anaerobic Glycolysis

NCT04320264
View directory record Official record
Conditions
Metabolic Inflexibility
Interventions
Weight loss surgery
Procedure
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 24, 2026, 2:20 AM EDT
Completed Not applicable Interventional Results available

Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea

NCT03194698
View directory record Official record
Conditions
Ocular Rosacea, Dry Eye
Interventions
Intense Pulsed Light Treatment (IPL), Meibomian Gland Expression
Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 24, 2026, 2:20 AM EDT